Trials / Completed
CompletedNCT01327924
Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone
Ease of Use and Tolerability of Norditropin NordiFlex® in Growth Hormone naïve Children: Impact on Daily Life
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 77 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Europe. The purpose of this study is to assess the impact on daily life for children new to using a growth hormone injection device.
Conditions
- Growth Hormone Disorder
- Growth Hormone Deficiency in Children
- Genetic Disorder
- Turner Syndrome
- Foetal Growth Problem
- Small for Gestational Age
- Chronic Kidney Disease
- Chronic Renal Insufficiency
- Delivery Systems
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Norditropin NordiFlex® | Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice. |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2011-04-04
- Last updated
- 2014-06-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01327924. Inclusion in this directory is not an endorsement.